Alnylam Pharmaceuticals (ALNY) Assets Average (2010 - 2026)
Alnylam Pharmaceuticals (ALNY) posted Assets Average of $5.0 billion for Q1 2026, up 2.83% on a QoQ basis from $4.9 billion in Q4 2025, and up 19.42% year-over-year from $4.2 billion in Q1 2025.
Alnylam Pharmaceuticals (ALNY) Assets Average (2010 - 2026) Analysis & Trends
Alnylam Pharmaceuticals' Assets Average history runs 17 years deep, the most recent figure standing at $5.0 billion for Q1 2026.
- Quarterly Assets Average rose 19.42% year-over-year to $5.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.0 billion (up 19.42% YoY) and the FY2025 annual result came in at $4.6 billion, up 14.08% from the prior year.
- Assets Average was $5.0 billion for Q1 2026 at Alnylam Pharmaceuticals, up from $4.9 billion in the prior quarter.
- Across five years, Assets Average topped out at $5.0 billion in Q1 2026 and bottomed at $3.4 billion in Q2 2022.
- A 5-year average of $4.0 billion and a median of $3.8 billion in 2023 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2023 — Assets Average retreated 1.96% — and 2026, when it increased 19.42%.
- Alnylam Pharmaceuticals' Assets Average stood at $3.5 billion in 2022, then increased by 8.29% to $3.8 billion in 2023, then gained by 10.12% to $4.2 billion in 2024, then rose by 16.26% to $4.9 billion in 2025, then gained by 2.83% to $5.0 billion in 2026.
- Business Quant data shows ALNY's Assets Average at $5.0 billion in Q1 2026, $4.9 billion in Q4 2025, and $4.7 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 303.40 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 65.01 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 40.89 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 8.37 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 26.06 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 40.71 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 795.91 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 2.30 Bn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 5.05 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.05 Bn |
| Dec 31, 2025 | 4.91 Bn |
| Sep 30, 2025 | 4.71 Bn |
| Jun 30, 2025 | 4.39 Bn |
| Mar 31, 2025 | 4.23 Bn |
| Dec 31, 2024 | 4.22 Bn |
| Sep 30, 2024 | 4.11 Bn |
| Jun 30, 2024 | 3.92 Bn |
| Mar 31, 2024 | 3.83 Bn |
| Dec 31, 2023 | 3.83 Bn |
| Sep 30, 2023 | 3.62 Bn |
| Jun 30, 2023 | 3.40 Bn |
| Mar 31, 2023 | 3.47 Bn |
| Dec 31, 2022 | 3.54 Bn |
| Sep 30, 2022 | 3.43 Bn |
| Jun 30, 2022 | 3.38 Bn |
| Mar 31, 2022 | 3.54 Bn |
| Dec 31, 2021 | 3.56 Bn |
| Sep 30, 2021 | 3.49 Bn |
| Jun 30, 2021 | 3.38 Bn |